Biopharma companies—including AstraZeneca, BioNTech and Agios—peered farther into the future on the second day of JPM, setting both revenue and R&D targets through the end of the decade.
The J.P. Morgan Healthcare Conference is widely known as an annual starting gun for the biopharma industry, giving companies a platform to lay out their strategies for the coming year. On day two, however, companies looked farther afield, giving near-term roadmaps for their businesses and setting sales and clinical targets through the end of the decade.
Some takeaways:
AstraZeneca Doubles Down on 2030 $80B Goal
At JPM, AstraZeneca’s Chief Financial Officer Aradhana Sarin said the company’s goal of hitting $80 billion in total revenue by 2030 is “very much within reach.”
To get there, the pharma expects to launch a clutch of high-value products in the near term, including its hypertension drug baxdrostat, for which a new drug application was accepted last month. AstraZeneca’s breast cancer candidate camizestrant and myasthenia gravis drug gefurulimab are also approaching the market.
Meanwhile, the pharma also draws confidence from its pipeline, particularly in cancer, for which it is testing eight wholly-owned clinical-stage antibody-drug conjugates (ADCs), as well as two cell therapies with potentially $5 billion in peak revenues.
Read more about AstraZeneca at JPM 2026 here.
BioNTech Continues Pivot From COVID to Cancer, With PD-1/VEGF at the Core
BioNTech continues to move away from COVID-19 and return to its cancer roots. At a company event on Tuesday, the pharma laid out its strategic goals for this year: accelerate its late-stage pipeline, focus on combination therapies and move from a platform-centered to a tumor-driven approach.
In a note to investors Tuesday evening, analysts at BMO Capital Markets said that pumitamig, BioNTech’s PD-1/VEGF bispecific antibody, “is at the heart” of the company’s 2026 strategy. Indeed, pumitamig is being studied both as a monotherapy—for breast cancer, hepatocellular carcinoma, colorectal cancer and different types of lung cancers—and as part of a combination regimen with ADCs. BioNTech is expecting a host of early- and late-stage readouts across its pumitamig program this year, as per a Monday release.
Among the potential pumitamig indications, “focus remains on the near-term Ph 3 1L [triple-negative breast cancer] China readout,” BMO said. Data from this trial, the analysts added, will help determine if pumitamig could become “a next-generation IO backbone.” For BioNTech, a lot is riding on pumitamig’s success. The drug is under a June 2025 partnership with Bristol Myers Squibb, which has promised up to $7.6 billion in milestones. The PD-1/VEGF space is quickly filling up with rivals, including AbbVie, which put nearly $5 billion on the line this week for ex-China rights to a candidate from RemeGen.
As for BioNTech, “With 8 pivotal studies across oncology indications, we could see the company shift into a commercial oncology company within the decade,” BMO said.
https://www.biospace.com/business/jpm26-day-2-companies-lay-out-near-term-revenue-longer-term-business-goals
